Edition:
United States

Alcobra Ltd (ADHD.O)

ADHD.O on Consolidated Issue listed on NASDAQ Global Market

1.12USD
22 Jun 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.12
Open
$1.12
Day's High
$1.13
Day's Low
$1.11
Volume
127,035
Avg. Vol
478,753
52-wk High
$5.36
52-wk Low
$0.83

ADHD.O

Chart for ADHD.O

About

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $30.87
Shares Outstanding(Mil.): 27.56
Dividend: --
Yield (%): --

Financials

  ADHD.O Industry Sector
P/E (TTM): -- 244.33 18.98
EPS (TTM): -0.89 -- --
ROI: -42.22 -7.97 -5.09
ROE: -42.22 -9.96 -4.32

BRIEF-Alcobra announces cooperation agreement with Brosh Group

* Alcobra announces cooperation agreement with Brosh Group and board additions

Jun 12 2017

BRIEF-Alcobra names David Baker interim CEO, replacing Daniely

* Yaron Daniely to step down as chief executive officer, effective May 31, 2017

May 15 2017

BRIEF-Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group

* Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group

May 05 2017

BRIEF-Alcobra Ltd says mailed proxy materials for extraordinary general meeting of shareholders

* Alcobra Ltd - "mailed proxy materials for extraordinary general meeting of shareholders, called by Brosh Capital L.P. and certain of its affiliates"

Apr 24 2017

BRIEF-Amir Efrati says reports 16.8 pct stake in Alcobra as of April 12

* Amir Efrati - on April 12, delivered notice to Alcobra to convene independent extraordinary general meeting of shareholders - SEC filing

Apr 12 2017

BRIEF-Amir Efrati reports 16.8 pct stake in Alcobra Ltd

* Amir Efrati reports 16.8 percent stake in Alcobra Ltd as on April 6, 2017

Apr 10 2017

BRIEF-Amir Efrati reports passive stake of 9 pct in Alcobra Ltd

* Amir Efrati reports passive stake of 9 percent in alcobra ltd as on Feb. 22, 2017

Feb 24 2017

BRIEF-Alcobra reports Q4 loss per share $0.22

* Alcobra announces fourth-quarter and full-year 2016 financial results and provides corporate update

Feb 15 2017

BRIEF-Amir Efrati reports 7.5 pct stake in Alcobra Ltd as of Jan. 23

* Amir Efrati reports 7.5 percent stake in Alcobra Ltd as of January 23 - sec filing

Feb 02 2017

Alcobra to stop testing sole drug for ADHD after study fails

Alcobra Ltd said it would abandon evaluating its only experimental drug to treat attention deficit hyperactivity disorder (ADHD), after a failed late-stage study, wiping away more than half the company's value before the bell on Tuesday.

Jan 17 2017

More From Around the Web

Earnings vs. Estimates